Company news
Exagen Inc. news in 2025
Exagen Inc.'s news releases, calls and decks from 2025, newest first.
Exagen Inc. to Participate in Fourth Quarter Investor Conferences
November 11, 2025
Exagen Inc. Reports Strong Q3 2025 Results
November 4, 2025
Exagen Announces Acceptance of Six Abstracts at 2025 American College of Rheumatology Convergence
October 23, 2025
Exagen Inc. to Announce Third Quarter 2025 Financial Results on November 4, 2025
October 21, 2025
Exagen Inc. to Participate in Third Quarter Investor Conferences
August 6, 2025
Exagen Inc. Reports Strong Q2 2025 Results
July 29, 2025
Exagen Inc. Appoints Chas McKhann to Board of Directors
July 17, 2025
Exagen Inc. to Announce Second Quarter 2025 Financial Results on July 29, 2025
July 15, 2025
Michael Mahler, PhD Joins Exagen as Chief Scientific Officer to Enhance Leadership in Autoimmune Diagnostics
June 23, 2025
Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter’s Option to Purchase Additional Shares
May 9, 2025
Exagen Inc. Prices Public Offering of Common Stock
May 8, 2025
Exagen Inc. Announces Proposed Public Offering of Common Stock
May 7, 2025
Exagen Inc. Reports Record Q1 2025 Revenue Driven by Growth in Average Selling Price and Testing Volume
May 5, 2025
Exagen Inc. Announces Senior Secured Credit Facility with Perceptive Advisors
April 28, 2025
Exagen Inc. to Announce First Quarter 2025 Financial Results on May 5, 2025
April 21, 2025
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2024 Results and Business Highlights
March 11, 2025
Exagen Inc. to Announce Fourth Quarter and Full-Year 2024 Financial Results on March 11, 2025
February 25, 2025
Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select Preliminary 2024 Financial Results
January 11, 2025
Calls in 2025
Decks in 2025
- Q1 2025 Earnings Presentation
Earnings · 28 slides · May 5, 2025